Blood biomarkers are taking off in the Alzheimer's disease field, showing promise for diagnosis, prognostication, and treatment monitoring. Following development, validation, and retrospective and prospective analyses, several assays are now ready for real-world study and clinical implementation. In today's podcast, our experts discuss the road to clinical implementation of plasma biomarkers, including the latest data on Aβ and GFAP, development of SOPs and guidelines, and real-world evidence.